InflaRx Investor Relations Material
Latest events
Investor Update
InflaRx
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from InflaRx N.V.
Access all reports
InflaRx N.V. is a clinical-stage biopharmaceutical company engaged in the discovery and development of drugs that inhibit the activation of the complement system, particularly targeting the C5a component, a potent inflammatory mediator. This focus addresses various autoimmune and other inflammatory diseases. The company's leading product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody with multiple clinical applications, including for diseases like hidradenitis suppurativa and cutaneous squamous cell carcinoma. The company is headquartered in Jena, Germany, and its shares are listed on the NASDAQ.
Key slides for InflaRx N.V.
Investor Update
InflaRx N.V.
Investor Update
InflaRx N.V.
Latest articles
Swoosh: The Nike Story
The Nike story and how the company rose to the top of its industry, as well as insights into the company philosophy and way of doing business.
17 May 2024
Burberry: From WWI Trench Coats to Global Luxury
Explore Burberry's journey from a small outfitter to a global luxury fashion icon under Daniel Lee's creative vision.
17 May 2024
Phil Knight: The Entrepreneurial Genius Behind Nike
The life, work, and legacy of Nike’s legendary founder Phil Knight and his path to the top of athletic footwear and apparel.
16 May 2024
Ticker symbol
Country
🇺🇸 United States